Background and objective: Metformin is an oral antidiabetic therapy (ADT) to manage type 2 diabetes mellitus (T2DM), and has been reported to have potential anti-tuberculosis (TB) effects. This study investigates the risk of active TB among persons with T2DM who were treated with various ADT and insulin therapies. Methods: We conducted a nationwide population-based cohort study using the Taiwan Longitudinal Health Insurance Database, including 49 028 T2DM patients who were metformin users (n = 44 002) or non-users (n = 5026). A total of 5026 propensity score-matched pairs of metformin users and non-users with T2DM were evaluated from 1998 to 2010. The data were analysed using Cox proportional hazard models. Results: Patients with T2DM had a significantly higher rate of incident TB than did the control subjects (adjusted hazard ratio: 2.01; 95% confidence interval (95% CI): 1.80-2.25). After adjusting for comorbidities, diabetes complications, ADT type and statin use, metformin use was an independent factor for predicting a reduced risk of active TB (adjusted relative risk (aRR): 0.24; 95% CI: 0.18-0.32). The association between metformin use and active TB risk was also consistent in most subgroup analyses, except for patients with metabolic disorders (aRR: 0.46; 95% CI: 0.11-1.87). This protective effect of metformin was dose-dependent but diminished gradually in the elderly population. Conclusion: Among all types of ADT and insulin therapies, metformin is the only agent with a decreased risk of active TB in the T2DM population. However, this effect was diminished in the elderly population and was not observed in patients with metabolic disorders.
INTRODUCTION
The association between diabetes mellitus (DM) and the development of active tuberculosis (TB) has been well established. 1, 2 In 2012, 15% of TB patients worldwide were attributable to DM; in fact, the number of adult TB patients associated with DM was 1 million, which is only slightly less than the number observed for human immunodeficiency virus (HIV)-associated TB. 3 Based on current predictions, the number of DM patients will increase to 642 million by 2040. 4 The World Health Organization has identified DM as an important and reemerging risk factor for TB. 5 Standardized anti-TB therapy is based on pathogen targeting and consists of treatment with a combination of medications over a long duration. 6 However, antimycobacterial resistance is an emerging problem in TB treatment; thus, the discovery of new anti-TB drugs is a critical issue. 7 In addition to the discovery of novel anti-TB drugs, host-targeted therapy focuses on the therapeutic modulation of host cell responses to improve pathogen eradication. These new strategies are referred to as adjunct therapies. 8 Several drugs that have been approved or are in clinical development have been implicated in anti-TB adjunct therapy, and their efficacy has been demonstrated in animal models. However, they have not been approved for clinical use. 9 Singhal et al. reported that metformin might be a potential adjunct anti-TB treatment by means of augmenting protective host-immune responses. 10 Recently, Pan et al. reported that metformin users had a reduced risk compared to sulphonylurea users in diabetic patients in Taiwan. 11 However, the association between the risk of active TB among DM patients who were treated with other oral anti-diabetic therapies (ADT) or insulin injection therapies is unclear.
In Taiwan, from 2005 to 2008, the estimated overall diabetes prevalence rates were 12.0% among men and 8.0% among women. 12 Taiwan is also an endemic TB area, with an intermediate burden of the disease. In 2008, 2009 and 2010, the incidence rates of TB in Taiwan were 57.8, 57.2 and 54.5 per 100 000 people, respectively. 13 We thus conducted a nationwide, populationbased, matched cohort study using the Taiwan National Health Insurance (NHI) database to investigate the risk of active TB among DM patients who were treated with various ADT and insulin therapies.
METHODS

Source population
The population for this study was taken from the National Health Insurance Research Database (NHIRD) in Taiwan. The NHI is a single-payer, compulsory programme that was implemented in Taiwan in 1995 and covers all forms of healthcare for the residents of Taiwan. 14 All citizens who have established a registered residence for at least 4 months in the Taiwan area must be enrolled in the NHI. The NHI includes a comprehensive claims database, including ambulatory care, outpatient services, inpatient services and prescription drugs. There are approximately 23.75 million individuals in this registry. We used a database (LHID2000) containing 1 million randomly selected subjects from the Taiwan NHIRD, which was developed for research purposes. A systematic random sampling method was used to build this representative database of 1 000 000 NHI enrollees. There were no statistically significant differences in age, sex, or healthcare costs between the sample group and all enrollees. This dataset spans from January 1998 to December 2010 and includes all claims data for these 1 000 000 individuals. Details of the LHID2000 database are presented on the National Health Research Institute's Web site (http://w3.nhri. org.tw/nhird/date_01.html).
The identification numbers of all subjects in the NHIRD were encrypted to protect the privacy of the individuals. All researchers who used the NHIRD and its data subsets were required to sign a written agreement declaring that they had no intention of attempting to obtain information that could potentially violate the privacy of the patients or care providers. With approval from the Ethics Review Board of Kaohsiung Medical University Hospital, we conducted a retrospective, nationwide, population-based cohort study (IRB No. 20160005 ).
Definition of study cohorts
This study enrolled patients who were 20-100 years old and who were newly diagnosed with type 2 diabetes mellitus (T2DM) (International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM): 250.X0 and 250.X2) between 1998 and 2010; patients with type 1 DM were excluded (ICD-9-CM code 2501). The diagnosis of T2DM was further confirmed by the baseline treatment, which included two or more monthly prescriptions of anti-diabetic medications prescribed by validated physicians. We also excluded individuals with confirmed active TB prior to their diagnosis of T2DM. Furthermore, for the T2DM cohort, we excluded those with a history of malignancy (ICD-9-CM: 140-208) and HIV infection (ICD-9 code 042) before their T2DM diagnosis date (Fig. 1) .
Definition of subcohorts, comorbidities and covariates
For each T2DM patient, one non-T2DM control was frequency matched regarding sex, age, region and the year that the T2DM diagnosis was obtained. Metformin users were enrolled in the study cohort on the date after their prescription of metformin. The index date was defined as the first day of metformin use. All patients were followed until death or the end of 2010. To avoid immortal time bias, we randomly assigned an index date to each metformin non-user according to the index date of a metformin user.
Patients with more severe diabetes are at higher risk for TB. 15 Because the baseline characteristics and diabetes severity might vary between metformin users and non-users in the original unmatched cohort, a 1:1 propensity score-matched analysis was conducted. For each metformin user and non-user, we calculated a propensity score to estimate the probability of metformin use. A propensity analysis was performed by using a logistic regression to obtain a 4-digit propensity score match for each patient with the covariates, such as age group, sex, regions, socioeconomic status, comorbidities and DM complications. Figure 1 is a flowchart of the procedures used to create an unmatched cohort and a cohort of 1:1 propensity-matched metformin users and non-users.
For each subject, the comorbidities records, including myocardial infarction (ICD-9-CM code 410412), congestive heart failure (ICD-9-CM code 428), peripheral vascular diseases (ICD-9-CM code 443. The diabetic complications included the following seven categories: cardiovascular disease, nephropathy, retinopathy, peripheral vascular disease, stroke, neuropathy and metabolic disorders. 16 These complicationassociated ICD-9-CM codes are listed in Table S1 of the Supplementary Information.
The oral ADT were categorized into five groups: metformin [Anatomical Therapeutic Chemical code (ATC code) A10BA], sulphonylureas (ATC code A10BB), meglitinides (ATC code A10BX), thiazolidinediones (TZD) (ATC code A10BG) and α-glucosidase inhibitors (ATC code A10BF). Insulin injection therapy was classified as rapid-acting (ATC code A10AB), intermediate-acting (ATC code A10AC), long-acting (ATC code A10AE) or combination (ATC code A10AD). These ADT were analysed for their effects on TB development in this T2DM study cohort.
Definition of TB
In Taiwan, TB is a notifiable infectious disease, and physicians are required by Communicable Disease Control law to report all patients who have suspected or confirmed TB to the government. In this study, active TB patients were confirmed by the Centers for Disease Control and Prevention, Taiwan. All healthcare services for TB management are funded through the NHI in Taiwan, and patients receive directly observed treatment. A recent analysis using a cross-matched TB notification database and a NHI reimbursement database found that over 96% of TB patients were registered in the TB registry. 17 We defined active TB as at least one outpatient visit or one hospital admission with ICD-9-CM codes for TB (010-018) during the follow-up period and the prescription of more than two anti-TB medications for more than 90 days during the study period. [18] [19] [20] 
Statistical analysis
The continuous and categorical variable data were analysed by t-tests and chi-square tests. To confirm the association between TB incidence and metformin use, a time-to-event analysis was used to estimate the probability that an event would occur at different points in time. The most common time-to-event statistical methods are Kaplan-Meier analyses and the proportional hazards model. Kaplan-Meier analyses were performed to estimate the differences in the risk of TB development between the cohorts. The proportional hazards assumption and proportional hazards model was applied to analyse the effects of single and multiple covariates on predicting whether TB would develop. All data processing and statistical analyses were performed Metformin reduces TB risk in diabetics with SAS software (Cary, NC, USA), version 9.3. The statistical significance level was set at a P value of <0.05.
RESULTS
Baseline characteristics of the study population
Our study cohort consisted of 49 028 patients of T2DM diagnosed between 1998 and 2010 in Taiwan; 44 002 patients took metformin, and 5026 had never used metformin ( Table 1 ). Most of the T2DM patients were treated with metformin for glycemic control (89.7%).
The main age distribution was between 41 and 70 years old (74.0% in metformin users and 70.9% in non-users).
The age and sex distributions differed significantly between these two groups in the unmatched cohort, with a mean age approximately 2 years older for metformin non-users; the non-users also had a greater proportion of men (53.4%) versus the metformin users (50.8%). Compared with the metformin non-users, the metformin users had higher prevalence rates of statin use (59.3% vs 45.2%, P < 0.001). However, in the propensity-matched cohort, both age and sex distributions were comparable, with no statistically significant differences between the two groups. The metformin cohort had higher prevalence rates of diabetic complications.
TB incidence among T2DM patients treated with or without metformin
Compared with the non-T2DM control subjects, the adjusted hazard ratio (aHR) in the T2DM cohort was 2.01 (95% confidence interval (95% CI): 1.80-2.25) after controlling for age, region, socioeconomic status and comorbidities (Tables S2 and S3 in Supplementary Information). According to a Kaplan-Meier analysis, the cumulative TB incidence was significantly higher in patients with T2DM than in the control group (log-rank test, P < 0.0001) ( Fig. S1 in Supplementary Information). Figure 2A ,B shows the cumulative incidences of TB in the metformin user and non-user cohorts (unmatched original cohort and matched cohort, respectively).
A significantly lower incidence of active TB was found in the T2DM patients who used metformin (P < 0.0001). This protective effect appeared progressively larger with the higher cumulative defined daily dose (cDDD), indicating the dose-dependent manner of metformin in this issue (Table S4 in Supplementary Information).
Active TB and T2DM severity, ADT and statin use
The proportional hazards assumption was satisfied for all variables because none of these time-dependent variables were significant, except for metformin use, duration of DM diagnosis and statin use variables. Comorbidities, diabetes complications, ADT type, statin use and the duration of DM diagnosis were included for analysis in a Cox proportional hazards regression model ( Table 2) . Both metformin and statin use were protective factors against active TB. Compared with metformin non-users, the adjusted relative risk (aRR) of active TB was 0.24 (95% CI: 0.18-0.32) in the metformin user cohort ( Table 2 ). The protective effect of metformin was consistent with the varied existence of diabetes complications. A test of interaction was not significant for statin users (P Interaction = 0.7345) ( Table 3) .
The association between active TB risk and ADT or insulin use is shown in Table 2 . After adjustment for the potential risk factors, the use of sulphonylureas, meglitinides, TZD, α-glucosidase inhibitors or insulin injection therapies all appeared to increase the active TB risk. The only ADT related to lower aRR for active TB was metformin. Detailed findings of the subgroups analyses are shown in Table 3 . The lower risk for active TB development associated with metformin use was consistent in most subgroups, except for patients with metabolic disorders (aRR: 0.46; 95% CI: 0.11-1.87). A statistical interaction between metformin and age was noted. The protective effect of metformin was statistically significant but diminished gradually with ageing.
DISCUSSION
This large, population-based study revealed a higher risk of TB in patients with T2DM than in patients without T2DM (aHR: 2.01; 95% CI: 1.80-2.25). Furthermore, the data showed a lower incidence of active TB in patients treated with metformin than in those treated without metformin (aRR: 0.24; 95% CI: 0.18-0.32). Our study revealed a dose-response relationship between the use of metformin and the risk of active TB, and this protective effect diminished with ageing.
Hyperglycemia has been shown to be significantly associated with the prevalence of active TB. 21 Compared to patients with adequate glycemic control (HbA1c < 7%), patients with poor glycemic control (HbA1c > 7%) were at an increased risk of active TB. 22 Alisjahbana et al. also found an increased risk of active TB in both impaired fasting glucose patients (odds ratio (OR): 4.2; 95% CI: 1.5-11.7) and T2DM patients (OR: 4.7; 95% CI: 2.7-8.1). 23 According to a systematic review, among cohort studies, people with DM had an approximately 1.16-7.83 times greater risk of developing TB than did people without DM. 24 Previously, one population-based study revealed that diabetic Taiwanese patients had a relative risk of 1.3 for developing TB after adjustment for confounding factors. 25 The results of our nationwide population-based cohort study showed that patients with T2DM are at a significantly higher risk of developing TB after adjusting for confounding factors (aHR: 2.01; 95% CI: 1.80-2.25); our findings are consistent with the findings of previous studies.
Metformin is a potential candidate for host-directed TB treatment. 26 Singhal et al. showed that metformin targeted multiple pathways in TB-directed immune responses. 10 In M. tuberculosis-infected mouse models, increased AMP-activated protein kinase (AMPK) activity caused by metformin improved autophagy and restricted mycobacterial growth by inducing mitochondrial Reactive oxygen species (ROS) production and increasing mycobacterial phagosome acidification. Thereafter, the authors tested the antimicrobial activity of metformin in a murine model, and they showed the enhanced efficacy of conventional anti-TB drugs, which reduced lung damage and promoted accumulation in the lung of both CD8+ T cells and CD4+ T cells, as determined by cytokine production. Genome-wide transcriptional analyses revealed that metformin treatment reduced the expression levels of inflammatory-associated genes, including genes encoding interferon. 10 Furthermore, the authors analysed a cohort of 220 diabetic patients of which 62 subjects had a latent TB infection (LTBI); in this group, metformin treatment lowered the likelihood of LTBI. 10 Metformin is a biguanide class oral ADT and is the most commonly prescribed therapy for patients with T2DM. It has established treatment efficacy and a good safety profile and has been recommended as the firstline treatment for T2DM. 27 Recently, in a case-control study in India, Marupuru et al. showed that metformin use was associated with a 3.9-fold reduction in TB incidence among diabetic patients. 28 However, they did not adjust for comorbidities or diabetic complications in the TB and non-TB groups; these factors may be associated with TB development. 28 There might be concerns that metformin is not suitable for glycemic control in all T2DM populations, especially for patients with impaired renal function. In addition, metformin could be replaced with other ADT or insulin therapy in .0001 † A propensity analysis was performed by using a logistic regression to obtain a 4-digit propensity score match for each patient with the following covariates: age, age group, sex, region, socioeconomic status, comorbidities and DM complications.
Data for continuous and categorical variables were analysed by t-tests or Wilcoxon rank sum tests and chi-square tests to make comparisons between diabetic patients with matched and without metformin use.
ADT, anti-diabetic therapy; DM, diabetes mellitus; ICD, International Classification of Diseases; IQR, interquartile range; SD, standard deviation; TB, tuberculosis; TZD, thiazolidinedione. Figure 2 Cumulative incidences of tuberculosis (TB) events in type 2 diabetic patients treated with/without metformin. (A) Differences in active TB events between metformin users (unmatched cohort) and non-users were compared using log-rank tests and Kaplan-Meier analyses (metformin users or nonusers vs non-type 2 diabetes mellitus (T2DM) patients, log-rank test P < 0.0001, <0.0001). (B) Differences in active TB events between metformin users (matched cohort) and non-users were compared using log-rank tests and Kaplan-Meier analyses (metformin users or nonusers vs non-T2DM patients, logrank test P < 0.0001, <0.0001). (---) Compared group, (-) without metformin use, (---) with metformin use. or chronic pulmonary disease (model 2) or renal disease/chronic pulmonary disease (model 3), oral ADT, and insulin injection therapy using a Cox proportional hazards regression model. Crude relative risk (RR) with 95% CI and their P values were calculated using a Cox proportional hazards regression model. Interactions between metformin use and statin use were tested using the Cox proportional hazards model with an added interaction term: metformin use (yes/no)* statin (yes/no) and potential risk factors (DM complication = 0, DM complication ≥ 1, and overall, P for interaction >0.05
ADT, anti-diabetic therapy; CI, confidence interval; DM, diabetes mellitus; RR, relative risk; TB, tuberculosis; TZD, thiazolidinedione.
Respirology ( more severe diabetic patients. To avoid these biases, we used a propensity score-matched analysis to adjust for these disparate conditions and a Cox proportional hazards regression model to evaluate whether other ADT yield similar beneficial effects. Most ADT had similar efficacies in reducing haemoglobin A1c values, 29 and our data showed that of the oral ADT and insulin injection therapies, metformin was the only agent that was associated with the protective effects against active TB (Table 2) . Therefore, we propose that the lower TB risks observed in T2DM patients taking metformin were associated not only with glycemic control but also with increased immune functions targeting multiple pathways by metformin itself. 10 Recently, Su et al. reported that statin treatment is associated with a decreased risk of active TB. 20 Although metformin users in the T2DM cohort had slightly higher rates of statin use in this study, metformin was still associated with a decreased risk of active TB after adjustment for statin use ( Table 2) . As metformin is the recommended first-line ADT in newly diagnosed diabetes, it would be important to evaluate if there was a difference in years of diabetes diagnosis between the two cohorts. Although our study revealed that metformin user with longer duration of diabetes (Table 1) , the association between metformin use and TB risk was also consistent in different years of diabetes diagnosis (Table 3) . For most subgroups analyses, the aRR of active TB in metformin users were significantly reduced (Table 3) , suggesting an independent association of metformin therapy with the risk of developing active TB.
The main strength of this study is the comprehensive and nationwide population-based data analysis that includes comparison of a large number of patients with and without T2DM, as well as a comparison of propensity score-matched T2DM patients with or without metformin treatment. First, we designed and analysed a population-based study that can contribute to the field by epidemiologically showing the protective role of metformin in patients with T2DM in a mid-prevalence TB country, such as Taiwan. Our study further clarifies that metformin is the only agent with a protective role among the various ADT (metformin, sulphonylureas, meglitinides, TZD and α-glucosidase inhibitors) and insulin therapies. Recently, Pan et al.
11 used a similar database and documented that metformin users had a reduced risk compared to sulphonylurea users, which is compatible with our findings. Second, this protective effect of metformin was dose-dependent, and we further clarify that this effect diminished with ageing. In a pooled analysis of 13 studies involving different ADT, elderly patients on metformin had a higher incidence of adverse events and discontinuations than the overall metformin population. 30 This may be related to the accumulation of metformin in the presence of renal insufficiency. 31, 32 In our study, the elderly population was associated with decreased metformin cDDD and higher ratio of renal disease (Table S5A ,B in Supplementary Information). Third, there was no protective effect in T2DM patients with metabolic disorders. Among those with metabolic disorders, the metformin users were more elderly and had more DM complications (Table S6 in Supplementary Information), which may attenuate the protective effect of metformin. Finally, the relationship of the non-T2DM group, T2DM with and without metformin use was clearly presented in our study ( Fig. 2A,B) . Because of the retrospective observational nature of the study, patients were matched and compared with the use of propensity scores to reduce confounding effects. However, this study has several limitations. First, time-related biases are always a concern for observational study designs. 33, 34 Although immortal time bias and time-window bias were not totally avoided in this study, our study design minimized the impact of these biases. The inclusion of all T2DM patients who did not use metformin and who had no prior history of TB as the control group not only avoided selection bias but also minimized the impact of time-related biases. Second, some well-known but unmeasured confounders, such as smoking history, environmental exposure, body mass index (BMI) and glycemic control status, were not available in the NHI database. Although the Taiwan NHIRD does not contain direct laboratory results, such as haemoglobin A1c levels, the presence of diabetic complications could be a surrogate of poor glycemic control in diabetes. 35 In addition, a recent study revealed a dose-response relationship between active TB infection rates and differing severities of diabetes. 36 Therefore, we used a 1:1 propensity score to minimize these differences in both groups (metformin users and non-users). Third, smoking has also been demonstrated to be associated with pulmonary TB and is also the most important risk factor for chronic pulmonary disease. 18 Because smoking status is not available in this dataset, chronic pulmonary disease was selected as a proxy for cigarette smoking in our study. 37 However, smoking status or intensity could have changed after the development of chronic pulmonary disease. Therefore, we should interpret this result carefully; this is a significant limitation of the study. Fourth, the relationship between BMI, diabetes and risk of TB was complex. A recent study used two retrospective cohorts in Taiwan, revealed that obesity had a harmful effect on TB mediated through diabetes but had a strongly protective effect not mediated through diabetes. 38 Because the Taiwan NHIRD does not contain the record of BMI, further prospective study is warranted to confirm the relationship between BMI, diabetes and the risk of TB. Fifth, we could not adjust for the rate of contact with known contagious TB patients in both cohorts, which might have mediated the association between DM and active TB risk.
This nationwide, population-based study revealed that metformin is associated with a significantly lower risk of active TB in a T2DM population. However, this effect was diminished in the elderly population and was not observed in patients with metabolic disorders. Further prospective studies should be initiated to develop metformin and its potential derivatives as a new preventive or adjunctive agent to use against TB. Figure S1 Cumulative incidence rate of active TB in patients with and without type 2 diabetes. Table S1 Diabetes complications developed from ICD-9-CM codes. 
